Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 79Triple Negative Breast Neoplasms 9Stomach Neoplasms 8Inflammatory Breast Neoplasms 6Carcinoma, Hepatocellular 6Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Sarcoma 2Primary Breast Cancer 2Pathologic Complete Response 2Lung Neoplasms 2Carcinoma, Ductal, Breast 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Resectable HER2-positive Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms 1Nasopharyngeal Carcinoma 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

pertuzumab 1Trastuzumab 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2 Positive Early Breast Cancer × Epirubicin × Clear all
NCT05883852 2023-06-27

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Fudan University

Phase 3 Recruiting
1,406 enrolled
Breast

HER2 Positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡